The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.
Steven Leonard Chapman net worth and biography

Steven Chapman Biography and Net Worth

CEO of Natera

Steven “Steve” Chapman is the CEO of Natera, a global leader in cell-free DNA testing with a focus on women's health, oncology, and organ health. Chapman has been in the role of CEO since 2019, and he also sits on the board of directors.

Chapman has been with Natera since 2010, previously serving as chief operating officer, chief commercial officer, senior vice president for commercial operations and vice president of sales. As COO, he led Natera’s commercial entry to the competitive non-invasive prenatal testing market, in which itsPanorama® test reached market leader-status despite being fourth to market.

In his role as CEO, Chapman has played an instrumental role in expanding Natera’s core technology to address new oncology and organ health markets, securing swift commercial growth for the Prospera™ transplant assessment test and establishing the company’s leadership in molecular residual disease testing via Signatera.™ During his tenure, the company has seen year-over-year growth in revenue of more than 40 percent, consistently outperforming earnings expectations.

Before joining Natera, he worked with Genzyme Genetics, a biotechnology company. While there, Chapman delivered record-breaking commercial growth and led strategies that altered pregnancy genetic testing. He started his career as a researcher in the human genetics department at the University of California, Los Angeles, where he earned his B.S. in microbiology, immunology and molecular genetics.

What is Steven Leonard Chapman's net worth?

The estimated net worth of Steven Leonard Chapman is at least $4.54 million as of January 23rd, 2023. Mr. Chapman owns 103,779 shares of Natera stock worth more than $4,539,293 as of January 28th. This net worth estimate does not reflect any other investments that Mr. Chapman may own. Additionally, Mr. Chapman receives a salary of $925,590.00 as CEO at Natera. Learn More about Steven Leonard Chapman's net worth.

How old is Steven Leonard Chapman?

Mr. Chapman is currently 44 years old. There are 5 older executives and no younger executives at Natera. Learn More on Steven Leonard Chapman's age.

What is Steven Leonard Chapman's salary?

As the CEO of Natera, Inc., Mr. Chapman earned a total compensation package of $23,304,147.00 in 2021. Mr. Chapman earned a salary of $525,732.00, stock awards of $14,031,437.00, options awards of $8,386,125.00, non-equity compensation of $391,153.00, and other compensation of $8,700.00. Learn More on Steven Leonard Chapman's salary.

How do I contact Steven Leonard Chapman?

The corporate mailing address for Mr. Chapman and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at [email protected] Learn More on Steven Leonard Chapman's contact information.

Has Steven Leonard Chapman been buying or selling shares of Natera?

During the past quarter, Steven Leonard Chapman has sold $547,961.80 of Natera stock. Most recently, Steven Leonard Chapman sold 5,370 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $41.56, for a transaction totalling $223,177.20. Following the completion of the sale, the chief executive officer now directly owns 103,779 shares of the company's stock, valued at $4,313,055.24. Learn More on Steven Leonard Chapman's trading history.

Who are Natera's active insiders?

Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.

Are insiders buying or selling shares of Natera?

During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 60 times. They sold a total of 96,087 shares worth more than $3,913,739.28. The most recent insider tranaction occured on January, 23rd when insider Daniel Rabinowitz sold 2,387 shares worth more than $99,203.72. Insiders at Natera own 10.3% of the company. Learn More about insider trades at Natera.

Information on this page was last updated on 1/23/2023.

Steven Leonard Chapman Insider Trading History at Natera

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2023Sell5,370$41.56$223,177.20103,779View SEC Filing Icon  
1/3/2023Sell8,212$39.55$324,784.6093,831View SEC Filing Icon  
12/28/2022Sell2,605$39.84$103,783.2085,210View SEC Filing Icon  
12/23/2022Sell1,660$42.30$70,218.0082,632View SEC Filing Icon  
12/7/2022Sell2,645$38.31$101,329.9580,985View SEC Filing Icon  
10/24/2022Sell905$42.41$38,381.0573,326View SEC Filing Icon  
10/3/2022Sell1,559$44.43$69,266.3772,457View SEC Filing Icon  
9/28/2022Sell2,606$44.04$114,768.2470,891View SEC Filing Icon  
9/23/2022Sell1,674$45.30$75,832.2068,313View SEC Filing Icon  
7/22/2022Sell886$46.26$40,986.3669,805View SEC Filing Icon  
7/5/2022Sell1,550$36.93$57,241.5068,916View SEC Filing Icon  
6/28/2022Sell2,619$39.01$102,167.1967,341View SEC Filing Icon  
6/23/2022Sell1,652$35.76$59,075.5264,777View SEC Filing Icon  
4/22/2022Sell894$36.14$32,309.1663,122View SEC Filing Icon  
4/4/2022Sell1,559$43.09$67,177.3162,242View SEC Filing Icon  
3/28/2022Sell2,605$39.63$103,236.15View SEC Filing Icon  
3/23/2022Sell1,682$40.60$68,289.20View SEC Filing Icon  
3/10/2022Sell1,147$42.16$48,357.52View SEC Filing Icon  
1/24/2022Sell3,686$59.95$220,975.70View SEC Filing Icon  
1/5/2022Sell4,995$82.61$412,636.95View SEC Filing Icon  
1/3/2022Sell29,167$88.27$2,574,571.09View SEC Filing Icon  
12/28/2021Sell2,604$91.34$237,849.36View SEC Filing Icon  
12/23/2021Sell1,657$93.00$154,101.00View SEC Filing Icon  
12/10/2021Sell1,145$91.33$104,572.85View SEC Filing Icon  
12/7/2021Sell4,726$91.99$434,744.74View SEC Filing Icon  
12/1/2021Sell7,219$90.80$655,485.20View SEC Filing Icon  
11/1/2021Sell6,652$115.64$769,237.28View SEC Filing Icon  
10/4/2021Sell6,653$108.65$722,848.45View SEC Filing Icon  
9/28/2021Sell2,698$109.72$296,024.56View SEC Filing Icon  
9/23/2021Sell1,649$125.67$207,229.83View SEC Filing Icon  
9/10/2021Sell80,826$119.72$9,676,488.72View SEC Filing Icon  
8/12/2021Sell33,356$101.66$3,390,970.9674,986View SEC Filing Icon  
7/6/2021Sell27,832$117.05$3,257,735.6077,755View SEC Filing Icon  
6/28/2021Sell2,604$117.57$306,152.2877,234View SEC Filing Icon  
6/23/2021Sell1,662$115.18$191,429.1670,588View SEC Filing Icon  
6/14/2021Sell26,092$103.61$2,703,392.1278,582View SEC Filing Icon  
6/10/2021Sell1,158$102.61$118,822.3879,714View SEC Filing Icon  
6/4/2021Sell4,709$97.51$459,174.5982,127View SEC Filing Icon  
5/14/2021Sell13,007$93.05$1,210,301.3572,752View SEC Filing Icon  
4/13/2021Sell41,650$104.21$4,340,346.50127,409View SEC Filing Icon  
4/5/2021Sell1,558$104.09$162,172.2246,037View SEC Filing Icon  
3/29/2021Sell11,476$83.95$963,410.2037,185View SEC Filing Icon  
3/23/2021Sell2,241$102.55$229,814.5529,210View SEC Filing Icon  
3/11/2021Sell17,922$99.63$1,785,568.8636,942View SEC Filing Icon  
3/9/2021Sell22,327$99.30$2,217,071.1038,059View SEC Filing Icon  
3/3/2021Sell1,390$115.00$159,850.0038,554View SEC Filing Icon  
2/1/2021Sell3,840$108.12$415,180.8037,689View SEC Filing Icon  
1/13/2021Sell8,155$115.00$937,825.0038,282View SEC Filing Icon  
1/4/2021Sell4,890$99.49$486,506.1038,722View SEC Filing Icon  
12/22/2020Sell5,056$105.48$533,306.8837,879View SEC Filing Icon  
12/10/2020Sell1,163$92.60$107,693.8029,667View SEC Filing Icon  
11/11/2020Sell94,379$77.98$7,359,674.4239,660View SEC Filing Icon  
11/4/2020Sell61,351$75.00$4,601,325.0039,088View SEC Filing Icon  
10/12/2020Sell210$75.00$15,750.00View SEC Filing Icon  
10/5/2020Sell11,185$71.24$796,819.4045,170View SEC Filing Icon  
9/22/2020Sell558$62.69$34,981.0225,332View SEC Filing Icon  
9/10/2020Sell1,184$60.77$71,951.6825,399View SEC Filing Icon  
9/4/2020Sell9,720$61.56$598,363.2032,823View SEC Filing Icon  
8/6/2020Sell61,565$55.00$3,386,075.0026,002View SEC Filing Icon  
7/6/2020Sell13,237$48.97$648,215.8927,675View SEC Filing Icon  
7/2/2020Sell11,678$49.06$572,922.6827,675View SEC Filing Icon  
6/24/2020Sell4,771$45.47$216,937.3729,321View SEC Filing Icon  
6/22/2020Sell39,354$45.09$1,774,471.8626,415View SEC Filing Icon  
6/16/2020Sell4,457$45.00$200,565.0026,433View SEC Filing Icon  
6/10/2020Sell17,304$42.38$733,343.5240,882View SEC Filing Icon  
4/3/2020Sell1,564$27.50$43,010.0011,196View SEC Filing Icon  
3/23/2020Sell7,424$24.10$178,918.402,268View SEC Filing Icon  
3/10/2020Sell1,147$33.36$38,263.922,297View SEC Filing Icon  
1/16/2020Sell139,340$35.00$4,876,900.0032,540View SEC Filing Icon  
1/7/2020Sell1,849$35.00$64,715.0024,571View SEC Filing Icon  
1/3/2020Sell4,739$32.01$151,695.3927,461View SEC Filing Icon  
12/23/2019Sell558$36.93$20,606.9415,519View SEC Filing Icon  
9/23/2019Sell559$33.53$18,743.2713,813View SEC Filing Icon  
9/20/2019Sell9,424$33.19$312,782.5622,120View SEC Filing Icon  
9/10/2019Sell1,155$29.50$34,072.504,525View SEC Filing Icon  
8/9/2019Sell98,996$33.00$3,266,868.0020,061View SEC Filing Icon  
6/24/2019Sell390$25.19$9,824.1010,242View SEC Filing Icon  
6/10/2019Sell794$24.79$19,683.269,919View SEC Filing Icon  
3/22/2019Sell384$20.20$7,756.808,007View SEC Filing Icon  
3/11/2019Sell3,410$16.00$54,560.0010,299View SEC Filing Icon  
12/24/2018Sell565$12.39$7,000.351,679View SEC Filing Icon  
10/12/2018Sell35,000$20.66$723,100.0024,240View SEC Filing Icon  
10/2/2018Sell35,000$23.76$831,600.0019,022View SEC Filing Icon  
9/26/2018Sell9,200$24.88$228,896.009,762View SEC Filing Icon  
9/24/2018Sell562$23.78$13,364.364,324View SEC Filing Icon  
9/19/2018Sell35,000$23.81$833,350.0018,919View SEC Filing Icon  
9/11/2018Sell45,000$25.16$1,132,200.0016,628View SEC Filing Icon  
6/25/2018Sell86,919$18.00$1,564,542.003,588View SEC Filing Icon  
3/26/2018Sell1,997$9.74$19,450.784,468View SEC Filing Icon  
See Full Table

Steven Leonard Chapman Buying and Selling Activity at Natera

This chart shows Steven Leonard Chapman's buying and selling at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Natera Company Overview

Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Read More

Today's Range

Now: $43.74
Low: $41.89
High: $44.21

50 Day Range

MA: $39.96
Low: $35.29
High: $43.74

2 Week Range

Now: $43.74
Low: $26.10
High: $74.82


659,164 shs

Average Volume

1,300,920 shs

Market Capitalization

$4.27 billion

P/E Ratio


Dividend Yield



The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.